The July 2026 FDA Peptide Vote, Explained

In late July, headlines announced that an FDA panel had "backed" BPC-157 and five other peptides. Within days, clinics were telling patients the peptides were now legal. They were not. What happened was real and it matters, but it was a first step in a long process, and it was taken against the advice of FDA's own scientists.

If you are considering peptide therapy, or you already use a peptide and want to know where you stand, this is the article to read first. We walk through what the committee is, what it voted on, what FDA's reviewers said, what has to happen next, and what none of it changes. Regulatory status in this area is moving quickly, so treat everything here as a snapshot as of mid-September 2026 and verify current status with FDA before relying on it.

How we got here: February to July 2026

For several years, many of the peptides most discussed online sat in what FDA calls "Category 2" of its interim compounding framework: bulk substances nominated for the 503A list that FDA had identified as raising significant safety risks. In practice, pharmacies that compounded from Category 2 substances risked enforcement action, and many legitimate pharmacies stopped. Our background article on how peptide regulation works explains the categories and the 503A and 503B pathways in detail.

Then the politics shifted.

• February 27, 2026. HHS Secretary Robert F. Kennedy Jr. announced a plan to revisit FDA's restrictions on a group of peptides.
• April 2026. FDA published a Federal Register notice on April 16 scheduling a PCAC meeting, and removed a number of peptides from Category 2 so they could be reviewed.
• July 23–24, 2026. The PCAC met at FDA's White Oak campus in Silver Spring, Maryland, and voted on seven substances.

The April step is widely misunderstood, so it is worth being precise. Being taken out of Category 2 did not move these peptides into Category 1 (substances that may be used while evaluation continues), and it did not put them on the 503A bulks list. It cleared the way for review. It was not permission to compound, and a pharmacy treating it that way was reading something into the notice that was not there.

What the PCAC is, and what it is not

The Pharmacy Compounding Advisory Committee is one of FDA's standing advisory committees. Its members include pharmacists, physicians and other experts, along with consumer and industry representatives. When FDA is considering whether a bulk drug substance should go on the 503A list, the law requires it to consult the committee.

Consult is the operative word. The committee hears FDA's analysis, hears from nominators and the public, discusses, and votes. The vote is a recommendation. FDA is not required to follow it. The agency usually gives advisory committee votes significant weight, and going against a committee is uncommon, but it has happened, and it is FDA, not the committee, that ultimately writes the rule.

For the 503A bulks list specifically, a recommendation is only the start. Adding a substance requires rulemaking under the Administrative Procedure Act: FDA publishes a proposed rule, the public comments, and FDA issues a final rule that can differ from the proposal. That is why a committee vote in July could not, on its own, change what a pharmacy may lawfully do in August.

The seven peptides and how each vote went

FDA evaluated each substance for specific nominated uses, not for everything it is marketed for online. That detail matters: BPC-157, for instance, was evaluated for ulcerative colitis, not for tendon injuries or general "recovery." Vote tallies below are in favor–against–abstaining, as reported by legal and trade press covering the meeting.

Two things stand out. First, none of these was a comfortable majority. Shift one or two votes on BPC-157, KPV or TB-500 and the headline flips. Second, the committee's advice ran in the opposite direction to the agency's analysis for six of the seven. You can read FDA's meeting page, agenda and briefing documents on the FDA advisory committee calendar.

We cover several of these substances individually: BPC-157, TB-500 and thymosin beta-4, and the sleep claims attached to emideltide and epitalon in peptides and sleep.

What FDA's own reviewers concluded

Before the meeting, FDA staff published briefing documents for each substance. Across all seven, the agency's position was consistent: the substances were not well characterized, and the human safety and effectiveness data were insufficient. FDA recommended against adding any of them.

The details are more revealing than the summary.

BPC-157

FDA's reviewers described the human evidence as short, small and insufficient to establish safety or effectiveness. The only study in the nominated condition that FDA could find was a 2005 meeting abstract (Ruenzi and colleagues) describing a two-week trial of a BPC-157 enema in 53 people with mild-to-moderate ulcerative colitis, 46 of whom completed it. The abstract lacked key methodological details. Beyond that, FDA identified a small safety study of rectal dosing in 24 healthy volunteers and a handful of pilot reports: knee injections in 17 people, bladder instillations in 12 and an intravenous infusion in 2. The briefing noted there were no human data at all for the subcutaneous, oral, nasal or transdermal routes, which are the routes most often sold.

TB-500

The TB-500 briefing was starker. FDA stated that neither the nomination nor its own literature search turned up any information on TB-500 being given to patients to treat any disease or condition. TB-500 is a seven-amino-acid synthetic fragment, not the full thymosin beta-4 protein, a distinction that matters because most of the human research people cite involves the full protein, not the fragment being sold.

Cross-cutting safety concerns

Several concerns recurred across the briefings:

• Immunogenicity. Peptides given by injection can provoke an immune response, and FDA noted this risk may be amplified by aggregation (peptide molecules clumping together) and by impurities.
• Characterization. Inconsistent naming, no USP monographs, and certificates of analysis that did not fully characterize impurities or aggregates.
• Approved alternatives. For several nominated uses, such as ulcerative colitis and wound healing, FDA-approved treatments already exist, which weighs against adding an unevaluated substance.

So why did the committee vote yes?

It would be too simple to say the committee ignored the evidence. Supporters made a practical argument: many Americans are already using these peptides, mostly from unregulated online sellers. Bringing them inside licensed pharmacies, with prescriptions, sterile compounding standards and a prescriber accountable for the patient, could reduce harm compared with the status quo. That argument has force, and it is the same logic behind many harm-reduction policies.

Opponents on the committee answered that putting a substance on the bulks list creates a false impression that it has been evaluated to the standard of an approved drug, when it has not. One member, as reported by TIME, worried aloud that the committee was responding to market demand rather than solid science.

News coverage from STAT, ABC News and TIME also reported criticism that some newly appointed committee members had professional ties to companies that sell or promote peptides. We are not in a position to judge any individual's conflicts, but it is part of the public record of the meeting, and it is one reason the rulemaking and public comment stages that follow deserve attention.

What has to happen before a pharmacy can lawfully compound these

An August 2026 analysis by the law firm Holland & Knight put it plainly: after the vote, these peptides still could not lawfully be compounded from bulk, and FDA retained its authority to take enforcement action. For that to change, one of two things must happen: FDA completes rulemaking, or Congress amends the statute.

The rulemaking route looks like this:

1. FDA decides what to propose. It weighs the committee's advice alongside its own analysis. It can propose adding all six, some, or none.
2. Proposed rule. FDA publishes a proposed rule in the Federal Register explaining its reasoning.
3. Public comment. Anyone, including pharmacies, clinicians, patients and manufacturers, can submit comments.
4. Final rule. FDA reviews comments and issues a final rule, which can differ from the proposal.
5. Effective date. Only then does a listed substance become eligible for 503A compounding from bulk, and still subject to every other 503A condition, including a valid prescription for an individual patient.

Notice-and-comment rulemaking commonly takes many months and sometimes years. No proposed or final rule adding these peptides had been reported as of mid-September 2026. Rules change, so check the Federal Register and FDA's compounding pages for the current position.

What the vote does not change

Even in the best case for supporters, a lot stays exactly the same.

• None of these peptides becomes FDA-approved. The 503A bulks list is a list of ingredients pharmacies may compound from. It is not a finding that a substance is safe or effective for anything. Compounded preparations are not FDA-approved products, full stop.
• "Research use only" vials remain outside the system. Online sellers labeling products "not for human consumption" were never part of the pharmacy framework and are not brought into it by this process. Nothing about their identity, purity, concentration or sterility has been verified, and nothing in this process changes that.
• Anti-doping rules are untouched. FDA's compounding decisions have nothing to do with the World Anti-Doping Agency's Prohibited List. USADA lists BPC-157 under S0 (non-approved substances), and thymosin beta-4 and its derivatives, including TB-500, appear under S2. Both classes are prohibited at all times for athletes subject to the WADA Code.
• The evidence base is the same as it was on July 22. A vote does not generate data. The human studies FDA summarized are still the human studies that exist.

How to read the next headline without being misled

This story will keep producing news, and much of it will be written quickly or by people with something to sell. A few translations help:

• "FDA panel approves…" Advisory committees do not approve anything. They recommend. Look for the words "proposed rule" or "final rule" before assuming anything has changed.
• "FDA proposes to add…" A real step, but not the last one. A proposed rule opens a comment period; it does not change what pharmacies may do.
• "Now available from licensed pharmacies." Ask which final rule, with what effective date, the pharmacy is relying on. A licensed pharmacy compounding a substance does not make that compounding lawful.
• "Cleared," "sanctioned" or "FDA-backed." These words have no formal meaning in compounding law. They are chosen because they sound like approval.

A useful rule of thumb: if a source tells you a peptide's legal status without telling you the date and the document it is relying on, treat it as marketing until you can check it yourself.

What comes next

FDA has signaled a second PCAC review expected in February 2027 covering five more substances: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and PEG-MGF. Expect the same pattern of briefing documents, public comment and a vote, and expect headlines to overstate whatever happens.

For peptides outside both meetings, such as ipamorelin, CJC-1295, AOD-9604, thymosin alpha-1 and selank, status has been in flux. We are deliberately not stating a specific current position for those here, because it is the kind of detail that goes stale fast. A clinician prescribing through a licensed pharmacy should be able to tell you exactly where a given substance stands on the day you ask.

What this means if you are considering one of these peptides

The honest answer for most people is: not much has changed yet in what a responsible clinician can offer you, and that is worth knowing before you spend money.

Here is what we would suggest:

• Be skeptical of anyone claiming these peptides are now "legal" or "FDA-cleared." Ask them which final rule they are relying on. There is not one yet.
• Separate the regulatory question from the medical one. Even if a peptide becomes lawful to compound, whether it is a reasonable choice for you depends on your history, your goals and evidence that is, for now, mostly from animals.
• Ask about approved options first. For many of the goals people bring to peptides, there are FDA-approved medicines or non-drug approaches with far stronger evidence.
• Use a script. Our nine questions to ask any peptide provider will quickly show whether a clinic understands the framework it is operating in.

If you would like to talk this through with a licensed clinician, our peptide therapy consultations start with your history and goals, not a product. We will tell you where each option stands legally and what the evidence does and does not show. Sometimes the right answer is an approved medication; sometimes it is labs and lifestyle changes; sometimes it is "this isn't right for you." You can book a consultation when you are ready.

Common questions

Did the FDA approve BPC-157 in July 2026?

No. An FDA advisory committee voted 8–6, with one abstention, to recommend adding BPC-157 to the list of bulk substances 503A pharmacies may compound from. That recommendation is non-binding, requires rulemaking before it has any legal effect, and would not amount to FDA approval even if adopted.

Can a pharmacy legally compound BPC-157 or TB-500 now?

As of mid-September 2026, legal analyses indicated these peptides still could not lawfully be compounded from bulk under 503A, and FDA could still take enforcement action. That changes only if FDA finalizes a rule adding them to the list. Verify the current status with FDA, as rules change.

How long will FDA take to decide?

There is no fixed deadline. FDA must decide what to propose, publish a proposed rule, take public comments and issue a final rule. That process often takes many months or longer, and FDA can adopt all, some or none of the committee's recommendations.

What happened to DSIP (emideltide)?

The committee voted 6–7, with one abstention, against recommending emideltide, a substance related to delta sleep-inducing peptide, for the 503A list. It was the only one of the seven the committee did not recommend.

Does this change anything for athletes?

No. FDA compounding decisions do not affect the WADA Prohibited List. BPC-157 and TB-500 remain prohibited for athletes subject to anti-doping rules. Our guide to peptides and drug testing covers this in more detail.